Skip to main content

Clinical trial NIVEAU - DSHNHL 2015-01

Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of B-cell lymphoma

Organ Non-Hodgkin lymphoma
Trial status Trial closed
Trial type
Interventional with experimental drug
Phase Trial phase 2/3
Academic trial Non
Sponsor LYSA LYmphoma
EudraCT Identifier 2016-002272-27
Inclusion criteria First relapse or progressionAgressive NHLAge > 65 YO or >18 yo and HCT-CI score > 2 or prior ASCT and not eligible for allogeneic transplantation
Last update